Stock Ratings / Health Care / PRVA / insiders

AVAH (65) ADUS (73) WGS (47) OPCH (75) ⌘ Pro Terminal →

Privia Health Group Inc. (PRVA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$22.00 +0.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.99

Privia Health Group Inc. (PRVA) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.81B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRVA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Privia Health Group Inc. (NASDAQ: PRVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $22.00 (+0.71% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PRVA ranks #213 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRVA compare to AVAH and ADUS in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), PRVA carries a Roarable D+ (56/100 RQD), trailing P/E of 122.6x, gross margin of —, and ROIC of 10.5%. By comparison, AVAH (Aveanna Healthcare Holdings Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC 15.7%, cap $2.89B) and ADUS (Addus HomeCare Corporation) posts a B grade (73/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while AVAH leads on capital efficiency (15.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRVA?

▼

Per PRVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759655), Privia Health Group Inc. generated $0 in revenue, $22.9M in net income, and $163.4M in free cash flow against $1.37B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.99 (-0.06%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRVA)Realized 20D OHLCV Swing Band: ±5.9%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY PRVA SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 4.1% FCF Margin ($163.4M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (55) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$21.45+4.6% Next Q

Q2 (-2Q)

Grade C-$22.44-1.2% Next Q

Q3 (-1Q)

Grade C-$22.16-0.7% Next Q

Current

Grade D+$22.00-0.4% Hist 90D α

Trajectory: D (48) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PRVA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, PRVA faces multiple-compression risk if 122.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.90) or 200D SMA ($22.66) invalidates the momentum regime and cuts Target Base ($21.80) toward Bear Floor ($17.00).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PRVA Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PRVA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PRVA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRVA)

✓Walkthrough of PRVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.24%⚡ TESTING RESISTANCE

2026-11-02O $21.84H $22.00L $21.84C $22.00VOL 869.0K

RES: $22.46SUP: $18.30SMA50: $20.90SMA200: $22.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRVA Butterfly Map → + Track PRVA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRVA)

Health Care Rank #213 of 1016 ⚔️ AVAH vs PRVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRVA vs. AVAH, ADUS, WGS, OPCH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Privia Health Group Inc. (PRVA) ranks #213 by composite RQD confidence (56/100, grade D+) and #214 by equity capitalization ($2.81B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. OPCH currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PRVA at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRVA ACTIVE Privia Health Group Inc.	D+	56/100	122.6x	—	10.5%	+0.71%	$2.81B	Benchmark Subject
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	+1.53%	$2.89B	/avah-vs-prva →
ADUS Addus HomeCare Corporation	B	73/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	/adus-vs-prva →
WGS GeneDx Holdings Corp. (Class A)	D	47/100	—	69.7%	-4.1%	+9.79%	$2.12B	/wgs-vs-prva →
OPCH Option Care Health Inc.	B	75/100	23.0x	19.3%	11.9%	+1.79%	$4.77B	/opch-vs-prva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759655

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Privia Health Group Inc. (PRVA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.9M, operating cash flow of $163.4M, and free cash flow of $163.4M (+49.5% YoY). On the balance sheet, PRVA closed FY2025 with $1.37B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$22.9M	$163.4M	$163.4M	$1.37B	—
FY2024 (FY)	2024-12-31	$0	$14.4M	$109.3M	$109.3M	$1.14B	—
FY2023 (FY)	2023-12-31	$0	$23.1M	$80.8M	$80.8M	—	—

3. PRVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRVA compare to AVAH and ADUS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRVA?

Where is PRVA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRVA last traded at $22.00 (+0.71% on volume of 869,002 shares), positioning the stock +5.26% above its 50-day simple moving average ($20.90) and -2.91% below its 200-day simple moving average ($22.66). Across its 52-week range of $18.92 to $28.82, PRVA sits at the 31.1% percentile with a 14-day RSI of 55.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.9% ($20.70 to $23.30).

PRVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PRVA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PRVA leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: PRVA RQD Cockpit PRVA 12M Forecast PRVA Earnings & Move PRVA Dividends & DRIP PRVA Insiders & 13F PRVA Whale Options PRVA Profit Sankey PRVA News & Why